This Week in Cancer Discovery

Premium

In Cancer Discovery this week, a team of US researchers reports on the different sensitivities of glioma-specific versus lung-cancer specific EGFR mutations to EGFR inhibitors. Activation of EGFR in glioblastoma occurs through mutations in the extracellular domain, and such glioblastomas usually respond poorly to the EGFR inhibitor erlotinib, unlike lung cancers with kinase-domain EGFR mutations, the authors write.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

Fareed Zakaria writes that instead of focusing solely on STEM-related courses, students would do well to pursue the liberal arts if they want to be technology innovators.

A Harvard Business Review study found four major patterns of gender biases and added that black and Latina scientists further had to navigate racial stereotypes.